β¨ Medicines Distribution Consents
2638 NEW ZEALAND GAZETTE, No. 110 21 JULY 2005
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Act-3
Active Ingredient: Ibuprofen 200mg
Dosage Form: Liquid filled capsule
New Zealand Sponsor: Wyeth Consumer Healthcare A Division of Wyeth (NZ) Limited
Manufacturer: Cardinal Health Australia 401 Pty Ltd trading as R.P.Scherer, Braeside, Victoria, Australia
Product: Raptiva
Active Ingredient: Efalizumab 125mg
Dosage Form: Powder for injection
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturers: Genentech Inc, South San Francisco, California, United States of America
Laboratoires Serono SA, Aubonne, Switzerland
Dated this 14th day of July 2005.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4614
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Cerezyme
Active Ingredient: Imiglucerase-rch 212U
Dosage Form: Powder for infusion
New Zealand Sponsor: Medra Services Limited
Manufacturer: Genzyme Corporation, Allston, Massachusetts, United States of America
Note: This consent is valid for 2 years from 29 July 2005.
Dated this 14th day of July 2005.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4611
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Relenza Rotadisk
Active Ingredient: Zanamivir 5mg
Dosage Form: Powder for inhalation
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Manufacturers: Glaxo Wellcome Production, Evreux, France
GlaxoSmithKline Australia Pty Ltd, Boronia, Victoria, Australia
Product: Varivax
Active Ingredient: Varicella vaccine 1,350PFU
Dosage Form: Suspension for injection
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturer: Merck & Co Inc, West Point, Pennsylvania, United States of America
Dated this 14th day of July 2005.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go4613
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2005, No 110
Gazette.govt.nz —
NZ Gazette 2005, No 110
β¨ LLM interpretation of page content
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare14 July 2005
Medicines Act, New Medicine, Ibuprofen, Efalizumab
- DON MATHESON, Deputy Director-General, Public Health
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare14 July 2005
Medicines Act, Provisional Consent, Imiglucerase-rch
- DON MATHESON, Deputy Director-General, Public Health
π₯ Consent to the Distribution of Changed Medicines
π₯ Health & Social Welfare14 July 2005
Medicines Act, Changed Medicine, Zanamivir, Varicella vaccine
- DON MATHESON, Deputy Director-General, Public Health